VGLS Projected Dividend Yield

VG Life Sciences Inc ( OTCBB : VGLS )

VG Life Sciences is a drug discovery and development company researching two primary technologies: Targeted Peptide Technology (TPT), and Metabolic Disruption Technology (MDT). Co.'s clinical-stage product candidate is an MDT therapy, which helps, in combination with other drugs, to fight cancers with solid tumors in situations where the cancer is resistant to the initial cancer drug therapy. Co.'s MDT trial was initially for ovarian cancer, but has since expanded to include other solid tumors, including those located in the breast, colon, liver, lung, and pancreas. Co.'s pre-clinical product candidate is a TPT therapy for HIV/AIDS using its designed peptide known as VG1177.

21 YEAR PERFORMANCE RESULTS